Literature DB >> 11896471

Human and rabbit cavernosal smooth muscle cells express Rho-kinase.

R W Rees1, T Ziessen, D J Ralph, P Kell, S Moncada, S Cellek.   

Abstract

Rho-kinase is an enzyme involved in the Ca2+-sensitizing pathway in smooth muscle cells. Inhibition of this enzyme has been recently demonstrated to elicit penile erection by relaxing cavernosal smooth muscle. We aimed to investigate the presence and activity of Rho-kinase in human cavernosal smooth muscle. Primary culture of smooth muscle cells from human and rabbit penile corpus cavernosum was developed, and cells showed characteristic myocyte morphology and alpha-actin immunoreactivity. The presence of Rho-kinase was demonstrated by indirect immunofluorescence and Western blotting. A specific inhibitor of Rho-kinase, Y-27632, inhibited in a concentration-dependent manner the kinase activity of the protein immunoprecipitated with anti-Rho-kinase antibody. These results demonstrate for the first time expression and activity of Rho-kinase in human penile cavernosal smooth muscle cells and suggest that these cells can provide a cellular model for the study of enzymes involved in Ca2+-sensitizing pathways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896471     DOI: 10.1038/sj.ijir.3900814

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  10 in total

Review 1.  Physiology of penile erection and pathophysiology of erectile dysfunction.

Authors:  Robert C Dean; Tom F Lue
Journal:  Urol Clin North Am       Date:  2005-11       Impact factor: 2.241

2.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

3.  Up-regulation of the RhoA/Rho-kinase signaling pathway in corpus cavernosum from endothelial nitric-oxide synthase (NOS), but not neuronal NOS, null mice.

Authors:  Fernanda B M Priviero; Li-Ming Jin; Zhekang Ying; Cleber E Teixeira; R Clinton Webb
Journal:  J Pharmacol Exp Ther       Date:  2010-01-21       Impact factor: 4.030

Review 4.  Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies.

Authors:  Ranan DasGupta; Clare J Fowler
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction.

Authors:  Trinity J Bivalacqua; Hunter C Champion; Mustafa F Usta; Selim Cellek; Kanchan Chitaley; R Clinton Webb; Ronald L Lewis; Thomas M Mills; Wayne J G Hellstrom; Philip J Kadowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

Review 6.  Looking to the future for erectile dysfunction therapies.

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation.

Authors:  Haroldo A Toque; Kenia P Nunes; Lin Yao; James K Liao; R Clinton Webb; Ruth B Caldwell; R William Caldwell
Journal:  J Sex Med       Date:  2013-04-08       Impact factor: 3.802

Review 8.  Vasoconstriction and vasodilation in erectile physiology.

Authors:  Thomas M Mills
Journal:  Curr Urol Rep       Date:  2002-12       Impact factor: 2.862

9.  Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa.

Authors:  Fabio Guagnini; Mara Ferazzini; Marco Grasso; Salvatore Blanco; Tiziano Croci
Journal:  J Transl Med       Date:  2012-03-23       Impact factor: 5.531

Review 10.  The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors.

Authors:  Stanisław Wroński
Journal:  Cent European J Urol       Date:  2014-08-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.